CONNECT WITH US
Tech

Tech

Breakthrough Glasses Slow Nearsightedness in Kids. We Try Stellest Ourselves

CNET - Tech logo

Published on

Add as a preferred source on Google
Breakthrough Glasses Slow Nearsightedness in Kids. We Try Stellest Ourselves

We break down the first FDA-approved myopia treatment glasses, candidate eligibility for kids, and daily wear expectations.

Half the world’s population is expected to be nearsighted in 25 years, and eye care professionals are pushing new treatments to slow the progression of worsening vision in kids. Essilor Stellest glasses became the first eyeglasses approved by the US Food and Drug Administration for controlling myopia in kids. Bridget Carey discovered her daughter is a candidate for the treatment, and walks through the journey of ordering and living with Stellest frames and lenses. 

Watch more from MedTech month on What The Future: Hands-On With First Humanoid Robot Surgeon
This Removable Brain-Computer Implant Feels ‘Like Telekinesis’

Timecode chapters
0:00 A new tech for kids’ eyesight
0:26 The growing myopia crisis and causes
0:50 How Stellest lenses work and long-term eye risks
3:32 Alternative treatments for myopia
4:09 Fitting, frames and features
5:46 Follow-up care and guarantee
6:22 Real-world results and final thoughts

Video credits
Host: Bridget Carey
Scripted by: Bridget Carey
Producer: Carly Marsh
Camera: Carly Marsh
Video editor: Jon Gomez
Thumbnail designer: Zooey Liao

The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.



Source link
Related Topics:Tech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.